Pregnancy-Induced Sweet's Syndrome Treated with Infliximab

Brigita D Smolovic; Mirjana D Gajic-Veljic; Milos M Nikolic; Damir F Muhovic

doi:10.1159/000494974

Pregnancy-Induced Sweet's Syndrome Treated with Infliximab

Med Princ Pract. 2019;28(2):196-198. doi: 10.1159/000494974. Epub 2018 Oct 30.

Authors

Brigita D Smolovic¹, Mirjana D Gajic-Veljic², Milos M Nikolic², Damir F Muhovic³

Affiliations

¹ Department of Gastroenterohepatology, Clinical Center of Montenegro, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro, petar.s@t-com.me.
² Department of Dermatovenereology, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.
³ Department of Gastroenterohepatology, Clinical Center of Montenegro, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro.

Abstract

Objective: To present a case of relapsing and resistant Sweet's syndrome that developed during pregnancy together with an onset of Crohn's disease, showing complete resolution with the use of infliximab.

Clinical presentation and intervention: A 30-year-old pregnant woman presented with fever, skin lesions, and diarrhea. Skin biopsy confirmed neutrophilic dermatosis and she was diagnosed with Crohn's disease after endoscopy. There was no recurrence of Sweet's syndrome outside of her pregnancy. During a previous pregnancy, while corticosteroids were ineffective, complete regression of skin lesions was achieved using infliximab.

Conclusion: The "off-label" use of infliximab is beneficial for relapsing and resistant Sweet's syndrome.

Keywords: Crohn’s disease; Infliximab; Pregnancy; Sweet’s syndrome.

Publication types

Case Reports

MeSH terms

Adult
Dermatologic Agents / therapeutic use*
Female
Humans
Infliximab / therapeutic use*
Pregnancy
Pregnancy Complications / drug therapy*
Sweet Syndrome / diagnosis
Sweet Syndrome / drug therapy*

Substances

Dermatologic Agents
Infliximab